Clinical trials: Skin Toxicity
Melanoma Stage IV, Melanoma Stage III
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
- Conditions
- Melanoma Stage IV, Melanoma Stage III, Immunotherapy, Toxicity, Drug
- Trial name
- NCT05652673
- Testing
- nivolumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Erasmus Medical Center
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Colorectal Cancer Metastatic, Skin Toxicity
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
The aim of this study is to test the role of cycline in the prevention of acne-like skin rash in metastatic colorectal patients treated with Cetuximab and intensified FOLFIRI.
- Trial name
- SKINUX (NCT01317433)
- Testing
- Doxycycline, Cetuximab
- Where
- 5 sites in France
- Volunteers
- 25 people
- Sponsor
- Institut Cancerologie de l'Ouest
Radiodermatitis; Acute, Radiation Dermatitis
Novel Skin Care Product for the Management of Acute Radiodermatitis
Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications.
- Trial name
- RTSkin (NCT04929808)
- Testing
- Hydrating emollient for acute radiodermatitis, Standard institutional skin care
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Jessa Hospital
Cancer., Melanoma.
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
This study is a clinical trial phase I/II. Its goal is to determine the safety, tolerability, immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen NY-ESO-1 combined with the adjuvant MPLA from B.
- Conditions
- Cancer., Melanoma., Ovarian Cancer., Lung Cancer.
- Trial name
- NCT01584115
- Testing
- NY-ESO-1 combined with MPLA, NY-ESO-1 combined with MPLA vaccine
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigação em Imunologia
Melanoma
Imatinib in Adult Patients With Metastatic Ocular Melanoma
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
- Trial name
- O-Mel-Inib (NCT00421317)
- Testing
- Imatinib
- Where
- 12 sites in France
- Volunteers
- 13 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer
Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart
This study investigates the Breathe Well device to test whether it is superior to the existing treatment standard of the Varian Realtime Position Management (RPM) system in assisting patients with deep inspiration breath hold.
- Trial name
- BRAVEHeart (NCT02881203)
- Testing
- Breathe Well, RPM
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- University of Sydney
Metastatic Breast Cancer, Advanced Breast Cancer
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
IMPORTANT study is a multicenter, open-label, prospective, randomized-controlled, non-inferiority trial with a pragmatic approach involving older patients (≥ 70 years old) with advanced hormone receptor (HR)-positive/human…
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity
- Trial name
- IMPORTANT (NCT06044623)
- Testing
- CDK 4/6 inhibitors, Endocrine therapy
- Where
- 12 sites in Finland, Greece and 4 more
- Volunteers
- 495 people
- Sponsor
- Region Örebro County
Stage II and III Breast Cancer
Melatonin as Adjuvant Therapy in Breast Cancer Patients
The study evaluate the effect of melatonin in improving quality of life and reducing post operative pain and chemotherapy-induced toxicity in breast cancer patients.
- Trial name
- MIQOL-B (NCT01557478)
- Testing
- Melatonin
- Where
- 2 sites in Thailand
- Volunteers
- 166 people
- Sponsor
- Khon Kaen University
Breast Cancer
Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Melatonin is an attractive candidate with anticancer activities previously reported in various preclinical and clinical studies.
- Trial name
- NCT07067307
- Testing
- melatonin
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
Melanoma Stage III or IV
CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
People who develop a type of skin cancer known as 'melanoma' are often treated with immunotherapy. The type of immunotherapy used for patients with melanoma is known as Immune Checkpoint Inhibitors (ICI).
- Trial name
- CARD-IO (NCT06605833)
- Testing
- 12-Lead ECG, Transthoracic Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer, Radiodermatitis
Photobiomodulation for Breast Cancer Radiodermatitis
A prospective single blind controlled randomized trial to evaluate the superiority of photobiomodulation (PBM) using LED-therapy in reducing the prevalence of radiodermatitis in breast cancer compared to usual local care.
- Conditions
- Breast Cancer, Radiodermatitis, Radiotherapy Side Effect, Radiation Dermatitis
- Trial name
- NCT04059809
- Testing
- Photobiomodulation
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- AC Camargo Cancer Center
Cancer-related Fatigue, Neutropenia, Malignant
PG2 Breast Cancer Evaluation in Adjuvant Medicine Study
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence.
- Trial name
- PG2 BEAM (NCT03314805)
- Testing
- Astragalus polysaccharides 500 mg, EC Chemotherapy
- Where
- 5 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- PhytoHealth Corporation
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
NATIENS: Optimal Management and Mechanisms of SJS/TEN
The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of…
- Trial name
- NATIENS (NCT02987257)
- Testing
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Breast Cancer
Outpatient Clinic for Late Outcome for Breast Carcinoma in MAASTRO Clinic.
In order to evaluate the late outcome in patients curatively treated for breast cancer, a special outpatient clinic will be developed. There are two main purposes of the outpatient clinic.
- Trial name
- NCT01978756
- Testing
- Outpatient clinic
- Where
- Netherlands
- Volunteers
- 387 people
- Sponsor
- Maastricht Radiation Oncology
Breast Cancer
Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)
The current study is aimed to evaluate various imaging methods, including multidetector computed tomography (MDCT) as potential surrogates to assess the degree of damage caused to the heart by radiation therapy to the breast, in…
- Trial name
- NCT01018719
- Testing
- MDCT, ECG, Echocardiography
- Volunteers
- 100 people
- Sponsor
- Western Galilee Hospital-Nahariya
Melanoma Stage III, Melanoma Stage IV
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV
- Trial name
- NCT04305145
- Testing
- Infliximab, Methylprednisolone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT
This research study is being done to carefully evaluate the effect of giving radiation therapy after temporary breast reconstruction.
- Trial name
- NCT01664091
- Testing
- post-mastectomy radiation therapy (PMRT), tissue expander (TE), acellular dermal matrix (ADM)
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
In this phase I study, the investigators want to vaccine with THERAVAC® (an inactivated toxin coupled to melanoma antigen) some patients with advanced metastatic melanoma disease.
- Trial name
- THERAVAC (NCT01331915)
- Testing
- Theravac
- Where
- Belgium
- Volunteers
- 23 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Tinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are Studied
Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai
this study is intended to find out the therapeutic efficacy of the siddha drug Kandhaga Rasayanam in Padarthamarai ( Ring worm infection )
- Trial name
- KR (NCT02238912)
- Testing
- kandhaga rasayanam
- Where
- India
- Volunteers
- 50 people
- Sponsor
- National institute of Siddha